



A
1200
1000
800
600
400
200
0
free FGF (pg/ml)
hFGF
mFGF
0
50
100
150
200
250
FLAG-sFGFR3 (ng/ml)
B
120
100
80
60
40
20
0
inhibition of
Erk phosphorylation (%)
*
***
***
10
100
1000
10000
FLAG-sFGFR3 (ng/ml)

Figure 1





D


	Treatment	Humerus	Femur	Tibia
wt	PBS	9.04 ± 0.58	10.05 ± 0.57	13.43 ± 0.64
	0.5ng sFGFR3	9.34 ± 0.21	10.52 ± 0.25 *	14.15 ± 0.19 **
	5ng sFGFR3	9.43 ± 0.17 *	10.82 ± 0.62 ***	14.5 ± 0.48 *
ach	PBS	8.59 ± 0.59 * ###	9.64 ± 0.49 ###	12.72 ± 0.68 * ##
	0.5ng sFGFR3	8.77 ± 0.24	9.72 ± 0.67 *	12.87 ± 0.42 *
	5ng sFGFR3	9.13 ± 0.53	10.24 ± 0.67 *	13.93 ± 1.06

(all values are in mm)

Figure 2


A

kyphotic index KI=[AB]/[CD]



	Treatment	KI	% of animals with kyphosis (KI<4)
wt	PBS	4,66 ± 0,72	0%
	0.5ng sFGFR3	5,39 ± 0,55	0%
	5ng sFGFR3	4,85 ± 0,64	0%
ach	PBS	3,46 ± 0,65 *	80% ***
	0.5ng sFGFR3	4,34 ± 0,71 #	17% * ##
	5ng sFGFR3	4,71 ± 0,68	6% ###


B



	Treatment	C7	T11	Lumbar compression§
wt	All groups	0%	0%	0%
ach	PBS	88.9%	70.1%	58.6%
	0.5ng sFGFR3	28.6% ##	28.6% ##	18.2% ##
	5ng sFGFR3	40.0% ##	0% ###	16.6% ##

Figure 3

A



	Treatment	Ratio L/W	
wt	PBS	1.94 ± 0.05	
	0.5ng sFGFR3	1.93 ± 0.05	
	5ng sFGFR3	1.96 ± 0.07	
ach	PBS	1.75 ± 0.07 ***	#
	0.5ng sFGFR3	1.77 ± 0.09	
	5ng sFGFR3	1.81 ± 0.09	

B




Figure 4